Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma

Part of paid clinical trials in Durham, North Carolina.

Sponsor
Duke University
Study ID
NCT00002988
Phase
PHASE1
Status
Completed

Conditions

  • Brain and Central Nervous System Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus carmustine in treating patients who have recurrent primary malignant glioma.

Key Dates

Start date
Apr 30, 1997
Status verified
Feb 2013
Primary completion
Nov 30, 2000
Completion
Nov 30, 2000

Study Design

Enrollment
36 participants (estimated)
Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
Duke Comprehensive Cancer CenterDurhamNorth Carolina27710-

Find similar trials in Durham, NC

By research site
Duke Comprehensive Cancer Center· Durham, NC

Related Studies